Resveratrol as an epigenetic therapy for flavivirus infection: A narrative review

Abstract

Flaviviruses are a group of positive-stranded RNA viruses that cause a broad spectrum of severe illnesses in humans worldwide. Clinical manifestations of flavivirus infections range from mild febrile illness to hemorrhage, shock, and neurological manifestations. Flavivirus infections cause a substantial global health impact, with an estimated more than 400 million cases of infections annually. Hence, an understanding of flavivirus-host interaction is urgently needed for new antiviral therapeutic strategies. In recent years, many aspects concerning epigenetic therapy for viral infections have been addressed, including methylation of the genome, acetylation/deacetylation of histone complex and microRNA regulation. In this context, we surveyed and reviewed the literature and summarized the epigenetic effects of resveratrol, a natural polyphenol with potential anti-viral properties, on flavivirus infections.

Keywords

Infectious diseases / Epigenetic / Resveratrol / Flavivirus / DNA methylation / Histone / Non-histone proteins / Micro-RNA

References

[1] Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nat Microbiol 2020; 5(6): 796-812.

[2] Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: A systematic analysis. Lancet Infect Dis 2016; 16(8): 935-941.

[3] Ladhani SN, O'Connor C, Kirkbride H, Brooks T, Morgan D. Outbreak of Zika virus disease in the Americas and the association with microcephaly, congenital malformations and Guillain–Barré syndrome. Arch Dis Child 2016; 101(7): 600-602.

[4] Gundamraj V, Hasbun R. Viral meningitis and encephalitis: An update. Curr Opin Infect Dis 2023; 36(3): 177-185.

[5] Ruzek D, Upanc TA, Borde J, Chrdle A, Eyer L, Karganova G, et al. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. Antiviral Res 2019; 164: 23-51.

[6] Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009; 23(7): 781-783.

[7] Sikder S, Kaypee S, Kundu TK. Regulation of epigenetic state by non-histone chromatin proteins and transcription factors: Implications in disease. J Biosci 2020; 45(1): 1-16.

[8] Saunthararajah Y. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Edu Program Book 2013; 1: 511-521. doi: 10.1182/asheducation-2013.1.511.

[9] Bohl SR, Bullinger L, Rücker FG. Epigenetic therapy: Azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol 2018; 11(5): 361-371.

[10] Treppendahl MB, Kristensen LS, Gr⊘nbæk K. Predicting response to epigenetic therapy. J Clin Invest 2014; 124(1): 47-55.

[11] Lieberman PM. Epigenetics and genetics of viral latency. Cell Host Microbe 2016; 19(5): 619-628.

[12] Fernandes GFS, Silva GDB, Pavan AR, Chiba DE, Chin CM, Dos Santos JL. Epigenetic regulatory mechanisms induced by resveratrol. Nutrients 2017; 9(11): 1201.

[13] Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 2010; 116(20): 4670-4676.

[14] Russo GL, Ungaro P. Epigenetic mechanisms of quercetin and other flavonoids in cancer therapy and prevention. In: Epigenetics of cancer prevention. Fairfax, VA: Elsevier; 2019, p. 187-202.

[15] Zhang L, Li Y, Gu Z, Wang Y, Shi M, Ji Y, et al. Resveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF-κB signaling pathway. PLoS One 2015; 10(2): e0116879.

[16] Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F, et al. Inhibition of influenza A virus replication by resveratrol. J Infect Dis 2005; 191(10): 1719-1729.

[17] Yiu CY, Chen SY, Chang LK, Chiu YF, Lin TP. Inhibitory effects of resveratrol on the Epstein-Barr virus lytic cycle. Molecules 2010; 15(10): 7115-7124.

[18] Docherty JJ, Fu MMH, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 1999; 43(3): 145-155.

[19] Evers DL, Wang X, Huong SM, Huang DY, Huang ES. 3, 4ʹ, 5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res 2004; 63(2): 85-95.

[20] Xie XH, Zang N, Li SM, Wang LJ, Deng Y, He Y, et al. Resveratrol Inhibits respiratory syncytial virus-induced IL-6 production, decreases viral replication, and downregulates TRIF expression in airway epithelial cells. Inflammation 2012; 35(4): 1392-1401.

[21] ter Ellen B, Kumar ND, Bouma E, Troost B, van de Pol D, van der Ende-Metselaar H, et al. Resveratrol and pterostilbene potently inhibit SARS-CoV-2 infection in vitro. bioRxiv 2020. https://doi.org/10.1101/2020.09.24.285940.

[22] Han YS, Penthala NR, Oliveira M, Mesplède T, Xu H, Quan Y, et al. Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay. J Med Virol 2017; 89(3): 397-407.

[23] Mohd A, Zainal N, Tan KK, AbuBakar S. Resveratrol affects Zika virus replication in vitro. Sci Rep 2019; 9(1): 1-11.

[24] Lee S, Mailar K, Kim MI, Park M, Kim J, Min DH, et al. Plant-derived purification, chemical synthesis, and in vitro/in vivo evaluation of a resveratrol dimer, viniferin, as an HCV replication inhibitor. Viruses 2019; 11(10): 890.

[25] Merino-Ramos T, Jiménez de Oya N, Saiz JC, Martín-Acebes MA. Antiviral activity of nordihydroguaiaretic acid and its derivative tetra-O-methyl nordihydroguaiaretic acid against West Nile virus and Zika virus. Antimicrob Agents Chemother 2017; 61(8): e00376-17. doi: 10.1128/AAC.00376-17.

[26] Takaoka M. Resveratrol, a new phenolic compound, from Veratrum grandiflorum. Nippon Kagaku Kaishi 1939; 60: 1090-1100.

[27] Chung IM, Park MR, Chun JC, Yun SJ. Resveratrol accumulation and resveratrol synthase gene expression in response to abiotic stresses and hormones in peanut plants. Plant Sci 2003; 164(1): 103-109.

[28] Medina-Aguilar R, Pérez-Plasencia C, Gariglio P, Marchat LA, Flores-Pérez A, López-Camarillo C, et al. DNA methylation data for identification of epigenetic targets of resveratrol in triple negative breast cancer cells. Data Brief 2017; 11: 169-182.

[29] Gao Z, Xu MS, Barnett TL, Xu CW. Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells. Biochem Biophys Res Commun 2011; 407(2): 271-276.

[30] Bagul PK, Deepthi N, Sultana R, Banerjee SK. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFκB-p65 and histone 3. J Nutr Biochem 2015; 26(11): 1298-1307.

[31] Lin C, Li H, Liu J, Hu Q, Zhang S, Zhang N, et al. Arginine hypomethylation-mediated proteasomal degradation of histone H4—an early biomarker of cellular senescence. Cell Death Differ 2020; 27(9): 2697-2709.

[32] Zhang Y, Dong Q, Liu C, Zhu Y, Qin X, Qi Z, et al. Resveratrol affects the migration and apoptosis of monocytes by blocking HMGB1/NF-κB pathway. Transi Cancer Res 2021; 10(8): 3647.

[33] Ma C, Wang Y, Dong L, Li M, Cai W. Anti-inflammatory effect of resveratrol through the suppression of NF-κB and JAK/STAT signaling pathways. Acta Biochim Biophys Sin 2015; 47(3): 207-213.

[34] Dhar S, Hicks C, Levenson AS. Resveratrol and prostate cancer: Promising role for microRNAs. Mol Nutr Food Res 2011; 55(8): 1219-1229.

[35] Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005; 6(8): 597-610.

[36] Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998; 19(3): 219-220.

[37] Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005; 74: 481-514.

[38] Jeltsch A, Ehrenhofer-Murray A, Jurkowski TP, Lyko F, Reuter G, Ankri S, et al. Mechanism and biological role of Dnmt2 in nucleic acid methylation. RNA Biol 2017; 14(9): 1108-1123.

[39] Janssens S, Schotsaert M, Karnik R, Balasubramaniam V, Dejosez M, Meissner A, et al. Zika virus alters DNA methylation of neural genes in an organoid model of the developing human brain. mSystems 2018; 3(1): e00219-17.

[40] Boehm D, Ott M. Host methyltransferases and demethylases: Potential new epigenetic targets for HIV cure strategies and beyond. AIDS Res Hum Retroviruses 2017; 33(S1): S8-S22.

[41] Zhao Y, Soh TS, Lim SP, Chung KY, Swaminathan K, Vasudevan SG, et al. Molecular basis for specific viral RNA recognition and 2ʹ-O-ribose methylation by the dengue virus nonstructural protein 5 (NS5). Proc Natl Acad Sci U S A 2015; 112(48): 14834-14839. doi: 10.1073/pnas.1514978112. Epub 2015 Nov 17.

[42] Zhang G, Hussain M, O’Neill SL, Asgari S. Wolbachia uses a host microRNA to regulate transcripts of a methyltransferase, contributing to dengue virus inhibition in Aedes aegypti. PNAS 2013; 110(25): 10276-10281.

[43] Gomes AVBT, de Souza Morais SM, Menezes-Filho SL, de Almeida LGN, Rocha RP, Ferreira JMS, et al. Demethylation profile of the TNF-α promoter gene is associated with high expression of this cytokine in dengue virus patients. J Med Virol 2016; 88(8): 1297-1302.

[44] Anderson D, Neri JI, Souza CR, Valverde JG, De Araújo JM, Nascimento MD, et al. Zika virus changes methylation of genes involved in immune response and neural development in Brazilian babies born with congenital microcephaly. J Infect Dis 2021; 223(3): 435-440.

[45] Benegiamo G, Vinciguerra M, Mazzoccoli G, Piepoli A, Andriulli A, Pazienza V. DNA methyltransferases 1 and 3b expression in Huh-7 cells expressing HCV core protein of different genotypes. Dig Dis & Sci 2012; 57(6): 1598-1603.

[46] Chen C, Pan D, Deng AM, Huang F, Sun BL, Yang RG. DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture. Virology 2013; 441(1): 57-65.

[47] Medicine NLo. Decitabine for coronavirus (COVID-19) pneumonia- Acute Respiratory Distress Syndrome (ARDS) treatment: DART trial (DART) ClinicalTrials gov. 2020. [Online]. Available from: https://clinicaltrials.gov/ct2/show/NCT04482621. [Accessed on 10 May 2023].

[48] Kala R, Tollefsbol TO. A novel combinatorial epigenetic therapy using resveratrol and pterostilbene for restoring estrogen receptor-α (ERα) expression in ERα-negative breast cancer cells. PLoS One 2016; 11(5): e0155057.

[49] Mirza S, Sharma G, Ralhan R, Parshad R, Gupta SD, Pandya P. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on dna methyltransferases and associated proteins. J Breast Cancer 2013; 16(1): 23-31.

[50] Qin W, Zhang K, Clarke K, Weiland T, Sauter ER. Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. Nutr & Cancer 2014; 66(2): 270-277.

[51] Youngblood B, Reich NO. The early expressed HIV-1 genes regulate DNMT1 expression. Epigenetics 2008; 3(3): 149-156.

[52] Lou XD, Wang HD, Xia SJ, Skog S, Sun J. Effects of resveratrol on the expression and DNA methylation of cytokine genes in diabetic rat aortas. Arch Immunol Ther Exp (Warsz) 2014; 62(4): 329-340.

[53] Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21(3): 381-395.

[54] Park SY, Kim JS. A short guide to histone deacetylases including recent progress on class II enzymes. Exp Mol Med 2020; 52(2): 204-212.

[55] Li R, Zhu J, Xie Z, Liao G, Liu J, Chen MR, et al. Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe 2011; 10(4): 390-400.

[56] Zhou J, Snyder AR, Lieberman PM. Epstein-Barr virus episome stability is coupled to a delay in replication timing. J Virol 2009; 83(5): 2154-2162.

[57] Adhya D, Dutta K, Kundu K, Basu A. Histone deacetylase inhibition by Japanese encephalitis virus in monocyte/macrophages: A novel viral immune evasion strategy. Immunobiology 2013; 218(10): 1235-1247.

[58] Nelson J, Roe K, Orillo B, Shi PY, Verma S. Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Res 2015; 122: 39-45.

[59] Zhou Y, Wang Q, Yang Q, Tang J, Xu C, Gai D, et al. Histone deacetylase 3 inhibitor suppresses hepatitis C virus replication by regulating Apo-A1 and LEAP-1 expression. Virol Sin 2018; 33(5): 418-428.

[60] Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007; 122(4): 596-606.

[61] Delgado FG, Cárdenas P, Castellanos JE. Valproic acid downregulates cytokine expression in human macrophages infected with dengue virus. Diseases 2018; 6(3): 59.

[62] Sato A, Saito Y, Sugiyama K, Sakasegawa N, Muramatsu T, Fukuda S, et al. Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication. J Cell Biochem 2013; 114(9): 1987-1996.

[63] Kozlov M, Kleymenova A, Konduktorov K, Malikova A, Kochetkov S. Selective inhibitor of histone deacetylase 6 (tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes. Biochemistry (Moscow) 2014; 79(7): 637-642.

[64] Ai T, Xu Y, Qiu L, Geraghty RJ, Chen L. Hydroxamic acids block replication of hepatitis C virus. J Med Chem 2015; 58(2): 785-800.

[65] Wu Y, Hou F, Wang X, Kong Q, Han X, Bai B. Aberrant expression of histone deacetylases 4 in cognitive disorders: Molecular mechanisms and a potential target. Front Mol Neurosci 2016; 9: 114.

[66] Choi SJ, Lee HC, Kim JH, Park SY, Kim TH, Lee WK, et al. HDAC 6 regulates cellular viral RNA sensing by deacetylation of RIG-I. EMBO J 2016; 35(4): 429-442.

[67] Venturelli S, Berger A, Böcker A, Busch C, Weiland T, Noor S, et al. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells. PLoS One 2013; 8(8): e73097.

[68] Zeng X, Pan X, Xu X, Lin J, Que F, Tian Y, et al. Resveratrol reactivates latent HIV through increasing histone acetylation and activating heat shock factor 1. J Agric Food Chem 2017; 65(22): 4384-4394.

[69] Ding L, Jiang P, Xu X, Lu W, Yang C, Zhou P, et al. Resveratrol promotes HSV-2 replication by increasing histone acetylation and activating NF-κB. Biochem Pharmacol 2020; 171: 113691.

[70] dos Santos Costa C, Rohden F, Hammes TO, Margis R, Bortolotto JW, Padoin AV, et al. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1–3 mRNA expression in human visceral adipocytes. Obes Surg 2011; 21(3): 356-361.

[71] Yang T, Li S, Zhang X, Pang X, Lin Q, Cao J. Resveratrol, sirtuins, and viruses. Rev Med Virol 2015; 25(6): 431-445.

[72] Zainal N, Chang CP, Cheng YL, Wu YW, Anderson R, Wan SW, et al. Resveratrol treatment reveals a novel role for HMGB1 in regulation of the type 1 interferon response in dengue virus infection. Sci Rep 2017; 7(1): 1-12.

[73] Yu JW, Sun LJ, Liu W, Zhao YH, Kang P, Yan BZ. Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1–AMPK signaling pathway. Int J Infect Dis 2013; 17(7): e539-e545.

[74] Koyuncu E, Budayeva HG, Miteva YV, Ricci DP, Silhavy TJ, Shenk T, et al. Sirtuins are evolutionarily conserved viral restriction factors. MBio 2014; 5(6): e02249-14. doi: 10.1128/mBio.02249-14.

[75] Ren JH, Tao Y, Zhang ZZ, Chen WX, Cai XF, Chen K, et al. Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J Virol 2014; 88(5): 2442-2451.

[76] Wang X, Liu R, Zhang W, Hyink DP, Das GC, Das B, et al. Role of SIRT1 in HIV-associated kidney disease. Am J Physiol–Renal Physiol 2020; 319(2): F335-F344.

[77] Li Q, He M, Zhou F, Ye F, Gao SJ. Activation of Kaposi's sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: Identification of sirtuin 1 as a regulator of the KSHV life cycle. J Virol 2014; 88(11): 6355-6367.

[78] Elesela S, Morris SB, Narayanan S, Kumar S, Lombard DB, Lukacs NW. Sirtuin 1 regulates mitochondrial function and immune homeostasis in respiratory syncytial virus infected dendritic cells. PLoS Pathog 2020; 16(2): e1008319.

[79] Yang M, Wei J, Huang T, Lei L, Shen C, Lai J, et al. Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells. Phytother Res 2021; 35(3): 1127-1129.

[80] Owczarczyk AB, Schaller MA, Reed M, Rasky AJ, Lombard DB, Lukacs NW. Sirtuin 1 regulates dendritic cell activation and autophagy during respiratory syncytial virus–induced immune responses. J Immunol 2015; 195(4): 1637-1646.

[81] He M, Gao SJ. A novel role of SIRT1 in gammaherpesvirus latency and replication. Cell Cycle 2014; 13(21): 3328-3330.

[82] Deng JJ, Kong KYE, Gao WW, Tang HMV, Chaudhary V, Cheng Y, et al. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochim Biophys Acta, Gene Regul Mech 2017; 1860(4): 491-501.

[83] Curtil C, Enache LS, Radreau P, Dron AG, Scholtès C, Deloire A, et al. The metabolic sensors FXR, PGC-1α, and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J 2014; 28(3): 1454-1463.

[84] Tang HMV, Gao WW, Chan CP, Cheng Y, Deng JJ, Yuen KS, et al. SIRT1 suppresses human T-cell leukemia virus type 1 transcription. J Virol 2015; 89(16): 8623-8631.

[85] Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F. Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD⁺-dependent SIRT1 activity. Life Sci 2009; 85(13-14): 484-489.

[86] Zou T, Yang Y, Xia F, Huang A, Gao X, Fang D, et al. Resveratrol Inhibits CD4⁺ T cell activation by enhancing the expression and activity of Sirt1. PLoS One 2013; 8(9): e75139.

[87] Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X, et al. Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts. PLoS One 2011; 6(11): e27081.

[88] Wang ZL, Luo XF, Li MT, Xu D, Zhou S, Chen HZ, et al. Resveratrol possesses protective effects in a pristane-induced lupus mouse model. PLoS One 2014; 9(12): e114792.

[89] Chytil F, Spelsberg T. Tissue differences in antigenic properties of non-histone protein-DNA complexes. Nat New Biol 1971; 233(41): 215-218.

[90] Biggar KK, Li SSC. Non-histone protein methylation as a regulator of cellular signalling and function. Nat Rev Mol cell Biol 2015; 16(1): 5-17.

[91] Djondjurov L, Ivanova E, Tsanev R. Two chromatin fractions with different metabolic properties of non-histone proteins and of newly synthesized RNA. Eur J Biochem 1979; 97(1): 133-139.

[92] Kleinsmith LJ. Phosphorylation of non-histone proteins in the regulation of chromosome structure and function. J Cell Physiol 1975; 85(S1): 459-475.

[93] Goodwin G, Johns E. Are the high mobility group non-histone chromosomal proteins associated with ‘active’chromatin? Biochim Biophys Acta, Nucleic Acids Protein Synth 1978; 519(1): 279-284.

[94] Wang L, He L, Bao G, He X, Fan S, Wang H. Ionizing radiation induces HMGB1 cytoplasmic translocation and extracellular release. Int J Radiat Med & Nuclear Med 2016; 40(2): 91.

[95] Tang D, Kang R, Xiao W, Jiang L, Liu M, Shi Y, et al. Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J Immunol 2007; 178(11): 7376-7384.

[96] Blair RH, Horn AE, Pazhani Y, Grado L, Goodrich JA, Kugel JF. The HMGB1 C-terminal tail regulates DNA bending. J Mol Biol 2016; 428(20): 4060-4072.

[97] Lu B, Antoine DJ, Kwan K, Lundbäck P, Wähämaa H, Schierbeck H, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Aca Sci 2014; 111(8): 3068-3073.

[98] Oh YJ, Youn JH, Ji Y, Lee SE, Lim KJ, Choi JE, et al. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 2009; 182(9): 5800-5809.

[99] Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. Front Physiol 2015; 6: 93.

[100] Wu F, Zhao ZH, Ding ST, Wu HH, Lu JJ. High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pac J Cancer Prev 2013; 14(10): 5789-5795.

[101] Kim YH, Kwak MS, Park JB, Lee SA, Choi JE, Cho HS, et al. N-linked glycosylation plays a crucial role in the secretion of HMGB1. J Cell Sci 2016; 129(1): 29-38.

[102] Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukocyte Biol 2005; 78(1): 1-8.

[103] Jung JH, Park JH, Jee MH, Keum SJ, Cho MS, Yoon SK, et al. Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J Virol 2011; 85(18): 9359-9368.

[104] de Carvalho GC, Borget MY, Bernier S, Garneau D, da Silva Duarte AJ, Dumais N. RAGE and CCR7 mediate the transmigration of Zika-infected monocytes through the blood-brain barrier. Immunobiology 2019; 224(6): 792-803.

[105] Fraisier C, Papa A, Almeras L. High-mobility group box-1, promising serological biomarker for the distinction of human WNV disease severity. Virus Res 2015; 195: 9-12.

[106] Rocha DC, Souza TMA, Nunes PCG, Mohana-Borges R, Paes MV, Guimarães GM, et al. Increased circulating levels of High Mobility Group Box 1 (HMGB1) in acute-phase Chikungunya virus infection: Potential disease biomarker. J Clin Virol 2022; 146: 105054.

[107] Borde C, Barnay-Verdier S, Gaillard C, Hocini H, Maréchal V, Gozlan J. Stepwise release of biologically active HMGB1 during HSV-2 infection. PLoS One 2011; 6(1): e16145.

[108] Barqasho B, Nowak P, Abdurahman S, Walther-Jallow L, Sönnerborg A. Implications of the release of high-mobility group box 1 protein from dying cells during human immunodeficiency virus type 1 infection in vitro. J Gen Virol 2010; 91(7): 1800-1809.

[109] Chen R, Huang Y, Quan J, Liu J, Wang H, Billiar TR, et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon 2020; 6(12): e05672.

[110] Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 2006; 43(8): 1023-1030.

[111] Qu Y, Zhan Y, Yang S, Ren S, Qiu X, Rehamn ZU, et al. Newcastle disease virus infection triggers HMGB1 release to promote the inflammatory response. Virology 2018; 525: 19-31.

[112] Ong SP, Lee LM, Leong YFI, Ng ML, Chu JJH. Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells. PLoS One 2012; 7(7): e41932.

[113] Zou SS, Zou QC, Xiong WJ, Cui NY, Wang K, Liu HX, et al. Brain microvascular endothelial cells-derived HMGB1 facilitates monocyte transendothelial migration favoring jev neuroinvasion. Front Cell Infect Microbiol 2021: 11: 771928. doi: 10.3389/fcimb.2021.771928.

[114] Yu S, Zhou X, Xiang H, Wang S, Cui Z, Zhou J. Resveratrol reduced liver damage after liver resection in a rat model by upregulating sirtuin 1 (SIRT1) and inhibiting the acetylation of high mobility group box 1 (HMGB1). Med Sci Monitor: Int Med J Exp & Clin Res 2019; 25: 3212.

[115] Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.

[116] Chin K, Zainal N, Sam S, AbuBakar S. The antiviral action of resveratrol against Zika virus through the regulation of interferon responses by HMGB1. Nat Prod J 2023; 13. https://doi.org/10.21203/rs.3.rs-1495329/v1.

[117] Hou X, Liu G, Zhang H, Hu X, Zhang X, Han F, et al. High-mobility group box 1 protein (HMGB1) from Cherry Valley duck mediates signaling pathways and antiviral activity. Vet Res 2020; 51(1): 1-15.

[118] Moisy D, Avilov SV, Jacob Y, Laoide BM, Ge X, Baudin F, et al. HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication. J Virol 2012; 86(17): 9122-9133.

[119] Chaudhary N, Srivastava S, Dave U, Ojha A, Guchhait P, Chandele A, et al. High-mobility group box 1 protein promotes dengue virus replication by interacting with untranslated regions of viral genome. Virus Res 2022; 309: 198668.

[120] Yu R, Yang D, Lei S, Wang X, Meng X, Xue B, et al. HMGB1 promotes hepatitis C virus replication by interaction with stem-loop 4 in the viral 5ʹ untranslated region. J Virol 2015; 90(5): 2332-2344.

[121] Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Stürzel CM, et al. Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. Cell Host Microbe 2016; 19(4): 504-514.

[122] Meltzer PS. Small RNAs with big impacts. Nature 2005; 435(7043): 745-746.

[123] Wu S, He L, Li Y, Wang T, Feng L, Jiang L, et al. miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. J Infect 2013; 67(4): 329-341.

[124] Sharma N, Verma R, Kumawat KL, Basu A, Singh SK. miR-146a suppresses cellular immune response during Japanese encephalitis virus JaOArS982 strain infection in human microglial cells. J Neuroinflammation 2015; 12(1): 1-16.

[125] Kanokudom S, Vilaivan T, Wikan N, Thepparit C, Smith DR, Assavalapsakul W. miR-21 promotes dengue virus serotype 2 replication in HepG2 cells. Antiviral Res 2017; 142: 169-177.

[126] Zhu X, He Z, Hu Y, Wen W, Lin C, Yu J, et al. MicroRNA-30e^* suppresses dengue virus replication by promoting NF-κB–dependent IFN production. PLoS Negl Trop Dis 2014; 8(8): e3088.

[127] Wu N, Gao N, Fan D, Wei J, Zhang J, An J. miR-223 inhibits dengue virus replication by negatively regulating the microtubule-destabilizing protein STMN1 in EAhy926 cells. Microbes & Infect 2014; 16(11): 911-922.

[128] Bayer A, Lennemann NJ, Ouyang Y, Sadovsky E, Sheridan MA, Roberts RM, et al. Chromosome 19 microRNAs exert antiviral activity independent from type III interferon signaling. Placenta 2018; 61: 33-38.

[129] Slonchak A, Shannon RP, Pali G, Khromykh AA. Human microRNA miR-532-5p exhibits antiviral activity against West Nile virus via suppression of host genes SESTD1 and TAB3 required for virus replication. J Virol 2016; 90(5): 2388-2402.

[130] Espinoza JL, Takami A, Trung LQ, Kato S, Nakao S. Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells. PLoS One 2012; 7(12): e51306.

[131] Chen XY, Zhang HS, Wu TC, Sang WW, Ruan Z. Down-regulation of NAMPT expression by miR-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation. Int J Biochem & Cell Biol 2013; 45(2): 292-298.

[132] Zhang HS, Wu TC, Sang WW, Ruan Z. MiR-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of SIRT1. Biochim Biophys Acta-Mol Cell Res 2012; 1823(5): 1017-1023.

[133] Chaudhuri AD, Yelamanchili SV, Marcondes MCG, Fox HS. Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuinl. FASEB J 2013; 27(9): 3720-3729.

[134] Zhang S, Liu L, Wang R, Tuo H, Guo Y, Yi L, et al. MicroRNA-217 promotes angiogenesis of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and FOXO3A. PLoS One 2013; 8(12): e83620.

[135] Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010; 31(9): 1561-1566.

[136] Goldberg AD, Allis CD, Bernstein E. Epigenetics: A landscape takes shape. Cell 2007; 128(4): 635-638.

[137] Chen M, Chen X, Song X, Muhammad A, Jia R, Zou Y, et al. The immune-adjuvant activity and the mechanism of resveratrol on pseudorabies virus vaccine in a mouse model. Int Immunopharmacol 2019; 76: 105876.

[138] Hu L, Shen H, Guo S. Inhibitory effects of resveratrol on inflammatory response in rat dental pulp. J Hard Tissue Biol 2022; 31(3): 135-140.

[139] Szende B, Tyihak E, Kiraly-Veghely Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 2000; 32(2): 88-92.